CU20190010A7 - PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS - Google Patents
PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDASInfo
- Publication number
- CU20190010A7 CU20190010A7 CU2019000010A CU20190010A CU20190010A7 CU 20190010 A7 CU20190010 A7 CU 20190010A7 CU 2019000010 A CU2019000010 A CU 2019000010A CU 20190010 A CU20190010 A CU 20190010A CU 20190010 A7 CU20190010 A7 CU 20190010A7
- Authority
- CU
- Cuba
- Prior art keywords
- alkylsulfonylpiperidin
- fluoroalkyl
- pyrimidin
- onas
- pyrid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
<p>Esta invención se relaciona con compuestos de tipo 5 pirido[2,3-d]pirimidin-7(8h)-onas 6-fluoroalquil-2-(alquilsulfonilpiperidin-4-il)amino sustituidas, de la fórmula general (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>y sales farmacéuticamente aceptables de los mismos, en los cuales R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q y r son como se definen en la presente, a composiciones farmacéuticas que comprenden tales compuestos y sales, y métodos para utilizar tales compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, incluyendo cáncer.</p> <p> </p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662371602P | 2016-08-15 | 2016-08-15 | |
US201762533347P | 2017-07-17 | 2017-07-17 | |
PCT/IB2017/054655 WO2018033815A1 (en) | 2016-08-15 | 2017-07-31 | Pyridopyrimdinone cdk2/4/6 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20190010A7 true CU20190010A7 (es) | 2019-10-04 |
CU24522B1 CU24522B1 (es) | 2021-06-08 |
Family
ID=59631834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000010A CU24522B1 (es) | 2016-08-15 | 2017-07-31 | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS |
Country Status (41)
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD3497103T2 (ro) * | 2016-08-15 | 2021-08-31 | Pfizer | Inhibitori de piridopirimidinonă CDK2/4/6 |
JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
JP2020097562A (ja) | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド[2,3−d]ピリミジン−7(8h)−オンの合成 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
KR20210114996A (ko) * | 2019-01-17 | 2021-09-24 | 화이자 인코포레이티드 | Cdk 억제제의 결정질 형태 |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
MA54947A (fr) | 2019-02-15 | 2021-12-22 | Incyte Corp | Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
KR20220003565A (ko) | 2019-04-19 | 2022-01-10 | 화이자 인코포레이티드 | Pah를 치료하기 위한 항증식제 |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020240360A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Cdk阻害剤を使用した組合せ療法 |
WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
US11427567B2 (en) | 2019-08-14 | 2022-08-30 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors |
CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
CN114555600B (zh) * | 2019-10-17 | 2024-03-01 | 辰欣药业股份有限公司 | 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物 |
CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
CN115551856A (zh) * | 2020-02-28 | 2022-12-30 | 重庆复尚源创医药技术有限公司 | 作为cdk2/4/6抑制剂的化合物 |
WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2(cdk2)高选择性氘代抑制剂 |
CN115702155A (zh) * | 2020-06-17 | 2023-02-14 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 |
WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
EP4214202A1 (en) | 2020-09-15 | 2023-07-26 | Pfizer Inc. | Solid forms of a cdk4 inhibitor |
WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022140472A1 (en) * | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022152259A1 (zh) * | 2021-01-15 | 2022-07-21 | 江苏先声药业有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
CN116456987A (zh) | 2021-06-09 | 2023-07-18 | 郑州同源康医药有限公司 | 用作cdk激酶抑制剂的化合物及其应用 |
WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
CN116390921A (zh) * | 2021-09-29 | 2023-07-04 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
WO2023092104A1 (en) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023249968A1 (en) * | 2022-06-22 | 2023-12-28 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
WO2024039903A2 (en) * | 2022-08-19 | 2024-02-22 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
US6413971B1 (en) | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
CA2271157A1 (en) | 1997-02-05 | 1998-08-06 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
IL150742A0 (en) * | 2000-01-27 | 2003-02-12 | Warner Lambert Co | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease |
EE200200506A (et) | 2000-03-06 | 2004-02-16 | Warner-Lambert Company | 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid |
WO2002064594A2 (en) | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
PL220952B1 (pl) * | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
BRPI0507852A (pt) | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
EP1931670B1 (en) * | 2005-10-07 | 2012-09-12 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k |
EP1940839B1 (en) * | 2005-10-07 | 2013-07-31 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha |
BRPI0716880A2 (pt) | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
RS20090104A (en) | 2006-09-15 | 2010-06-30 | Pfizer Products Inc. | Pyrudo (2,3-d)pyrimidinone compounds and their use as p13 inhibitors |
EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
EP2139484B9 (en) * | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
CN102015704A (zh) * | 2008-04-29 | 2011-04-13 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
CN102177161A (zh) | 2008-10-22 | 2011-09-07 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
TW201300385A (zh) * | 2011-04-08 | 2013-01-01 | Afraxis Inc | 用於治療cns病症和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮 |
AR086209A1 (es) * | 2011-04-29 | 2013-11-27 | Exelixis Inc | METODO DE TRATAMIENTO CONTRA EL LINFOMA CON INHIBIDORES DE PIRIDOPIRIMIDINONA DE PI3K/mTOR, COMPUESTO, COMPOSICION FARMACEUTICA |
TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
WO2013126656A1 (en) * | 2012-02-23 | 2013-08-29 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
EP3431475B1 (en) | 2013-02-21 | 2021-04-07 | Pfizer Inc | Solid forms of a selective cdk4/6 inhibitor |
AR095464A1 (es) | 2013-03-15 | 2015-10-21 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y usos de los mismos |
US20160304466A1 (en) * | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
US9760610B2 (en) | 2014-07-31 | 2017-09-12 | Linkedin Corporation | Personalized search using searcher features |
CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
MD3497103T2 (ro) * | 2016-08-15 | 2021-08-31 | Pfizer | Inhibitori de piridopirimidinonă CDK2/4/6 |
-
2017
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 CN CN202210092651.2A patent/CN114394966A/zh active Pending
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 MX MX2019001849A patent/MX2019001849A/es unknown
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en active Application Filing
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko active IP Right Grant
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-01 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190010A7 (es) | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS | |
CO2020013149A2 (es) | Derivados de 2-amino-piridina o de 2-amino-pirimidina como inhibidores de quinasas dependientes de ciclinas | |
NI201400023A (es) | Derivados de pirrolopirimidina y purina | |
UY38553A (es) | Inhibidores de cdk2 | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
NI201600072A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
PE20150965A1 (es) | Azaindolinas | |
ECSP18056196A (es) | Derivados de indano | |
CU20140033A7 (es) | Derivados de pirrolopirimidina y purina | |
ECSP14013253A (es) | Derivados de pirrolopirimidina y purina | |
ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico |